Serous Cystadenocarcinoma — Variants & evidence

Serous Cystadenocarcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

1 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items (1 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CCNE1 Amplification1
Akt Inhibitor MK2206 + DinaciclibCombination	Ovarian Serous Cystadenocarcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID1735 A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors PMID 27663592 · Au-Yeung et al., 2017 · Open in CIViC	civic

Data updated 8 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.